Global Mergers and Acquisitions (M&A) Deals in 2021 - Top Themes in the Pharmaceuticals Sector - Thematic Research

Global Mergers and Acquisitions (M&A) Deals in 2021 - Top Themes in the Pharmaceuticals Sector - Thematic Research

Summary

This report analyzes the disruptive themes that have driven M&A activity in 2021 in the Pharma Sector

M&A deal value in global Pharma sector grew by 15%, from $191 billion in 2020 to $219 billion in 2021. In terms of deal volume, 2021 saw 908 deals compared to 795 in the previous year, recording a growth of 14%. There were 44 billion-dollar-plus M&A deals in the pharma sector in 2021, compared to 28 in the previous year.

Scope

• This report provides an overview of merger and acquisition activity globally in 2021 in Pharma Sector
• It identifies the themes driving most notable to deals announced in 2021 in the Pharma Sector

• Companies who invest in the right themes become success stories; those who miss the big themes end up as failures. If you want to understand the themes that drive an industry, simply look at the list of recent mergers and acquisitions (M&A).
• In this report we have listed down the most notable deals in Pharma sector to make it easy for our clients to get a view of themes disrupting the sector and prepare for the future.

Companies Mentioned

Novo Nordisk
Merck & Co
Perrigo Co
Sanofi
Pfizer
EQRx
Bayer
Amgen
PerkinElmer
Vitrolife
Danaher
MorphoSys
Thermo Fisher Scientific
ICON
Jazz Pharmaceuticals
Horizon Therapeutics
Dicerna Pharmaceuticals
Acceleron Pharma
Laboratoire HRA Pharma
Kadmon Holdings
Trillium Therapeutics
CM Life Sciences III
Vividion Therapeutics
Translate Bio
TeneoBio
Biolegend
Igenomix
Aldevron
Constellation Pharmaceuticals
PPD
Five Prime Therapeutics
Pandion Therapeutics
PRA Health Sciences
GW Pharmaceuticals
Viela Bio
Kymab
Laboratory Corp of America
Novartis
Synthetic Biologics
Pacira BioSciences
ProPhase Labs
XOMA
UniQure
Brooklyn ImmunoTherapeutics
Nexturn Bio
XERIS Pharmaceuticals
Roivant Sciences
Royalty Pharma 
Renovacor
Intec Pharma
VG Acquisition
Ensysce Biosciences
Personal Genome Diagnostics
Gyroscope Therapeutics
VCN Biosciences
Flexion Therapeutics
Nebula Genomics
Kuros Biosciences
Corlieve Therapeutics
Novellus Therapeutics
RosVivo Therapeutics
Strongbridge Biopharma
Montes Archimedes
Tidal Therapeutics
Chardan Healthcare Acquisition
Decoy Biosystems
23andMe
CSL
StepStone Group
Triley Bidco
Murano Bidco
Amunix Operating
Vifor Pharma
Arena Pharmaceuticals
Clinigen Group
CM Life Sciences III
Vectura Group
Vaccitech
Sagard Holdings
Beijing Pharmaceutical Investment and Management
Catalent
Compass Therapeutics
Athenex
Takeda Pharmaceutical
Grifols
Celularity
Avidea Technologies
AnaptysBio
Immunotech Biopharm
RheinCell Therapeutics
TRIGR Therapeutics
Kuur Therapeutics
Montes Archimedes Acquisition
Maverick Therapeutics
GigaGen
Silicon Therapeutics
GX Acquisition